文献速递眼底病与葡萄膜炎

视网膜色素上皮与微胶质细胞移植治疗年龄相关性黄斑变性

Retinal Pigment Epithelium and Microglia Transplantation in Age-related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2026-07-25

本文综述了利用人胚胎干细胞和多能干细胞平台重建外层视网膜的研究进展,重点评估了极化视网膜色素上皮单层和稳态微胶质样细胞的诱导分化、培养与质量验证。文章比较了单细胞悬液与生物工程贴片、无支架细胞片等移植构型对整合与视力恢复的影响,并讨论了CRISPR-Cas9基因编辑(包括碱基编辑和先导编辑)纠正补体因子H风险变体、敲除MHC-II及工程化CSF1R突变等免疫调节策略。

要点

  • 干细胞来源的极化RPE单层和稳态微胶质样细胞是外层视网膜重建的关键移植物。
  • 移植构型(单细胞悬液vs贴片/细胞片)影响移植后整合、视力恢复及细胞回流等不良事件。
  • 基因编辑可纠正CFH风险变体、消除MHC-II表达并工程化CSF1R突变以替代促炎宿主微胶质。

核心结论

  • 结合结构、分子和免疫调节策略的干细胞移植是恢复晚期黄斑变性中心视力和实现永久神经血管挽救的下一代临床前沿。

研究设计与样本

  • 本文为综述,综合了人胚胎干细胞和多能干细胞平台用于外层视网膜重建的当前进展。

主要发现

  • 单细胞悬液与生物工程贴片、无支架细胞片和先进细胞条带在移植后整合和视力恢复方面存在差异,并需平衡细胞回流和视网膜前膜形成等操作不良事件。
  • 将同种异体构建体移植到炎症性衰老宿主微环境面临微环境挑战。
  • 敲除II类反式激活因子以消除MHC-II表达可规避宿主T细胞免疫监视并在非人灵长类中防止移植物排斥。
  • 工程化CSF1R点突变使外源性微胶质在选择性小分子压力下竞争并替代适应不良的促炎宿主微胶质。

关键数值与推荐

  • CRISPR-Cas9基因组编辑范式包括胞嘧啶碱基编辑和先导编辑,旨在纠正补体因子H风险变体等细胞内在遗传脆弱性。
  • 未来方向强调多层双侧共移植模型,将基因编辑RPE贴片与稳态微胶质或视网膜类器官结合以实现持久突触修复,并配合自动化人工智能制造流程。

临床怎么用

  • 临床转化需关注移植构型选择对整合和视力恢复的影响,并平衡细胞回流和视网膜前膜形成等操作不良事件。
  • 基因编辑策略如敲除MHC-II和工程化CSF1R突变可用于规避免疫排斥和替代促炎微胶质。

局限性

  • 移植到炎症性衰老宿主微环境仍面临微环境挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Age-related macular degeneration (AMD) remains a leading cause of irreversible blindness worldwide, characterized by the progressive breakdown of the outer blood-retinal barrier, accumulation of protein and lipid deposits in the subretinal space, and the consequential degeneration of macular photoreceptors. Geographic atrophy (GA) is one of the blinding end points of AMD. While current pharmaceutical interventions can slow lesion expansion or counter choroidal neovascularization, they fail to address the most significant clinical unmet need: regeneration of damaged retinal tissue to restore vision. Regenerative medicine via stem cell transplantation offers a definitive curative approach by replacing the structural and immune framework of the outer retina. This review synthesizes current advancements in human embryonic and pluripotent stem cells platforms engineered for outer retinal reconstruction. We evaluate the differentiation, culturing, and quality validation required to generate clinical-grade, polarized RPE monolayers and homeostatic microglia-like cells. Structurally, single-cell suspensions are contrasted against bioengineered patches, scaffold-free cell sheets, and advanced cell strips, analyzing how graft configuration dictates post-transplantation integration and visual recovery while balancing procedural adverse events like cell reflux and epiretinal membrane formation. Furthermore, this review addresses the microenvironmental challenges of transplanting allogeneic constructs into an inflamed, senescent host niche. We examine CRISPR-Cas9 genome editing paradigms, including cytosine base and prime editing, designed to rectify cell-intrinsic genetic vulnerabilities such as the complement factor H (CFH) risk variant. We highlight translational applications, such as knocking out the Class II transactivator to eliminate major histocompatibility complex class II (MHC-II) expression, which successfully circumvents host T-cell immune surveillance and prevents graft rejection in non-human primates. Additionally, we analyze how engineering an inhibitor-resistant colony-stimulating factor 1 receptor (CSF1R) point mutation enables exogenously administered microglia to robustly outcompete and replace maladaptive, pro-inflammatory host microglia under selective small-molecule pressure. Finally, we discuss future directions, emphasizing multi-lineage bilayered co-transplantation models that combine genome-edited RPE patches with homeostatic microglia or retinal organoids to achieve durable synaptic repair, alongside automated artificial intelligence manufacturing pipelines. Together, these combined structural, molecular, and immune-modulating strategies represent the next clinical frontier in restoring clear central vision and achieving permanent neurovascular rescue in advanced macular degeneration.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Surawatsatien N, Solanky RM, van de Werken RP, et al. Retinal Pigment Epithelium and Microglia Transplantation in Age-related Macular Degeneration. Am J Ophthalmol. 2026. PMID: 42501956. doi:10.1016/j.ajo.2026.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。